ranging from rare inherited conditions like hemophilia
to common acute events with strong
nonhereditary triggers such as venous thromboembolism
(VTE), nonmalignant blood disorders comprise
a group of diverse conditions that are increasingly recognized
as important illnesses to be addressed by the public
health sector.1,2 These conditions currently affect millions
of Americans, and their prevalence is expected to grow
over the next several decades owing to improvements in
treatment, leading to increased life expectancy of people
with hereditary conditions like sickle cell disease (SCD)
and hemophilia and the rising occurrence of risk factors for
VTE.3–5